4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $10.59, for a total transaction of $17,314.65. Following the transaction, the insider owned 3,594 shares in the company, valued at $38,060.46. The trade was a 31.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total value of $19,256.00.

4D Molecular Therapeutics Stock Performance

FDMT opened at $10.84 on Friday. The company has a market cap of $619.34 million, a price-to-earnings ratio of -2.89 and a beta of 2.96. 4D Molecular Therapeutics, Inc. has a one year low of $2.23 and a one year high of $12.34. The business’s fifty day moving average is $9.68 and its two-hundred day moving average is $6.51.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. On average, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter worth approximately $41,000. Farther Finance Advisors LLC raised its stake in 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the period. Abich Financial Wealth Management LLC purchased a new position in 4D Molecular Therapeutics during the third quarter worth approximately $80,000. Inscription Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $94,000. Finally, Impact Partnership Wealth LLC purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $96,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

FDMT has been the topic of several recent research reports. Roth Capital reduced their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Royal Bank Of Canada boosted their price target on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.70.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.